In conclusion, GB-2, theaflavin, and theaflavin 3-gallate demonstrate significant potential as inhibitors of the ACE2–RBD interaction in Omicron variants, highlighting their therapeutic promise against COVID-19. Here, ACE2 is linked to COVID-19.